Table 2 Antimicrobial agents in β-lactam monotherapy and azithromycin combination therapy.

From: Azithromycin combination therapy for community-acquired pneumonia: propensity score analysis

Antimicrobial agentsβ-lactam monotherapy n = 952Azithromycin combination therapy n = 179P value
Ampicillin61 (6.4)13 (7.3)0.62
Sulbactam/ampicillin590 (62.0)61 (34.1)<0.001
Tazobactam/piperacillin41 (4.3)3 (1.7)0.14
Ceftriaxone246 (25.8)97 (54.2)<0.001
Cefepime2 (0.2)0 (0)1.0
Cefozopran1 (0.1)0 (0)1.0
Meropenem11 (1.2)5 (2.8)0.16
  1. Oral form at 500 mg/day for 3 days in 18 patients and at 2 g/day single dose in 146 patients; by injection at 500 mg/day in 15 patients.